UA99624C2 - Сульфонаміди як trpm8-модулятори - Google Patents

Сульфонаміди як trpm8-модулятори

Info

Publication number
UA99624C2
UA99624C2 UAA201001698A UAA201001698A UA99624C2 UA 99624 C2 UA99624 C2 UA 99624C2 UA A201001698 A UAA201001698 A UA A201001698A UA A201001698 A UAA201001698 A UA A201001698A UA 99624 C2 UA99624 C2 UA 99624C2
Authority
UA
Ukraine
Prior art keywords
sulfonamides
trpm8 modulators
compounds
trpm8
modulators
Prior art date
Application number
UAA201001698A
Other languages
English (en)
Russian (ru)
Inventor
Шон Т. Брейнум
Реймонд В. Колберн
Скотт Л. Дакс
Крістофер М. Флорес
Мішель С. Джеттер
І. Лю
Дональд Лудовікі
Марк Дж. Месілаг
Джей М. Меттьюз
Джеймс Дж. Макналлі
Лаура М. Ріні
Рональд К. Расселл
Нін Цинь
Кеннет М. Уеллс
Скотт С. Йуеллс
Марк А. Янгман
Крістофер Телеха
Original Assignee
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39772848&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA99624(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В.
Publication of UA99624C2 publication Critical patent/UA99624C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Даний винахід стосується сполук, композицій і способів лікування різних захворювань, синдромів, станів і розладів, що супроводжуються болем. Дані сполуки представлені формулою (І): EMBED ISISServer , (I) де А, В, G, Y, R1, R2, R3 і R4 визначають у даному винаході.
UAA201001698A 2007-07-18 2008-07-18 Сульфонаміди як trpm8-модулятори UA99624C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95045607P 2007-07-18 2007-07-18
PCT/US2008/070425 WO2009012430A1 (en) 2007-07-18 2008-07-18 Sulfonamides as trpm8 modulators

Publications (1)

Publication Number Publication Date
UA99624C2 true UA99624C2 (uk) 2012-09-10

Family

ID=39772848

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201001698A UA99624C2 (uk) 2007-07-18 2008-07-18 Сульфонаміди як trpm8-модулятори

Country Status (27)

Country Link
US (3) US8153682B2 (uk)
EP (1) EP2183239B1 (uk)
JP (1) JP5539868B2 (uk)
KR (1) KR101538391B1 (uk)
CN (1) CN101801949B (uk)
AR (1) AR067602A1 (uk)
AU (3) AU2008275927B8 (uk)
BR (1) BRPI0815096A2 (uk)
CA (1) CA2693159C (uk)
CL (1) CL2008002132A1 (uk)
CO (1) CO6251375A2 (uk)
CR (1) CR11284A (uk)
EA (1) EA201070158A1 (uk)
EC (1) ECSP109921A (uk)
GT (1) GT201000015A (uk)
IL (1) IL203295A (uk)
JO (1) JO2853B1 (uk)
MX (1) MX2010000690A (uk)
MY (1) MY153971A (uk)
NI (1) NI201000013A (uk)
NZ (1) NZ582555A (uk)
PA (1) PA8790401A1 (uk)
TW (1) TWI446909B (uk)
UA (1) UA99624C2 (uk)
UY (1) UY31239A1 (uk)
WO (1) WO2009012430A1 (uk)
ZA (1) ZA201001157B (uk)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8216547B2 (en) 2008-07-18 2012-07-10 Janssen Pharmaceutica Nv Radiolabelled TRP M8 receptor ligands
US20100104638A1 (en) * 2008-10-27 2010-04-29 Wei-Guo Dai Extended release oral acetaminophen/tramadol dosage form
WO2010080397A1 (en) * 2008-12-18 2010-07-15 Janssen Pharmaceutica Nv Sulfamides as trpm8 modulators
US8148422B2 (en) 2008-12-18 2012-04-03 Janssen Pharmaceutica, Nv Sulfonamides as TRPM8 modulators
CA2758071C (en) 2009-04-06 2018-01-09 Agios Pharmaceuticals, Inc. Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
KR20140071518A (ko) * 2009-05-01 2014-06-12 라퀄리아 파마 인코포레이티드 Ｔｒｐｍ8 길항제로서의 설파모일 벤조산 유도체
TW201103941A (en) * 2009-06-10 2011-02-01 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as TRPM8 channel modulators
TW201105681A (en) * 2009-06-10 2011-02-16 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as TRPM8 channel modulators
ES2352398B1 (es) * 2009-06-25 2011-09-29 Institut Univ. De Ciencia I Tecnologia S.A. N-fenetilsulfonamidas-n-sustituidas para la identificacion de actividad biologica y farmacologica.
US20120122920A1 (en) * 2009-06-26 2012-05-17 Josep Castells Boliart Libraries of n-substituted-n-phenylethylsulfonamides for drug discovery
DK2448582T3 (en) 2009-06-29 2017-07-17 Agios Pharmaceuticals Inc QUINOLIN-8 SULPHONAMIDE DERIVATIVES WITH ANTICANCER ACTIVITY
PL2448581T3 (pl) 2009-06-29 2017-06-30 Agios Pharmaceuticals, Inc. Kompozycje terapeutyczne i odnośne sposoby ich stosowania
US20120122710A1 (en) * 2009-07-01 2012-05-17 Josep Castells Boliart Libraries of n-substituted-n-phenylethylsulfonamides for the identification of biological and pharmacological activity
BR112012010220A2 (pt) 2009-10-30 2021-02-23 Janssen Pharmaceutical N.V. piridinas fenóxi-substituídas como modulares do receptor opioide
DE102010002558A1 (de) 2009-11-20 2011-06-01 Symrise Ag Verwendung physiologischer Kühlwirkstoffe und Mittel enthaltend solche Wirkstoffe
JP2013538784A (ja) * 2010-10-01 2013-10-17 ラクオリア創薬株式会社 Ｔｒｐｍ８拮抗剤としてのスルファモイル安息香酸ヘテロ二環性誘導体
CA2820075A1 (en) 2010-12-09 2012-06-14 Janssen Pharmaceutica Nv Imidazo [1, 2-a] pyridine sulfonamides as trpm8 modulators
MX2013006900A (es) 2010-12-17 2013-10-17 Agios Pharmaceuticals Inc Nuevos derivados n-(4-(azetidina-1-carbonil)fenil)-(hetero-)arilsu lfonamida como moduladores piruvato quinasa m2 (pmk2).
EP2655350B1 (en) 2010-12-21 2016-03-09 Agios Pharmaceuticals, Inc. Bicyclic pkm2 activators
US8906384B2 (en) * 2010-12-22 2014-12-09 The United States Of America As Represented By The Secretary Of Agriculture Antiviral activity of bovine type III interferon against foot-and-mouth disease virus
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
EP2481727A1 (en) 2011-01-28 2012-08-01 Dompe S.p.A. TRPM8 receptor antagonists
WO2012120398A1 (en) 2011-03-04 2012-09-13 Pfizer Limited Aryl substituted carboxamide derivatives as trpm8 modulators
BR112013023330B8 (pt) 2011-03-16 2022-09-27 Mitsubishi Tanabe Pharma Corp Compostos de sulfonamida tendo atividade antagonista trpm8
SI3406251T1 (sl) 2011-05-03 2024-05-31 Agios Pharmaceuticals, Inc. Aktivatorji piruvat kinaze za uporabo v terapiji
WO2012151440A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
SI2793883T1 (en) 2011-12-19 2018-08-31 Dompe Farmaceutici S.P.A. Antagonists TRPM8
EP2606888A1 (en) 2011-12-19 2013-06-26 Dompe' S.P.A. Trpm8 antagonists
JP5985453B2 (ja) * 2012-09-14 2016-09-06 田辺三菱製薬株式会社 医薬組成物
WO2014042238A1 (ja) 2012-09-14 2014-03-20 田辺三菱製薬株式会社 スルホンアミド化合物
EP2774919A1 (en) * 2013-03-06 2014-09-10 Pharmeste S.R.L. In Liquidazione Novel sulfonamide TRPA1 receptor antagonists
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
JP2016524609A (ja) * 2013-05-24 2016-08-18 ネステク ソシエテ アノニム メントール及び／又はイシリンを用いるうつ病の処置又は予防
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
CN105705610B (zh) * 2013-08-23 2018-01-30 巴斯夫欧洲公司 具有端杂芳基氰基亚乙烯基的化合物及其在有机太阳能电池中的应用
ES2724111T3 (es) 2014-06-23 2019-09-06 Dompe Farm Spa Derivados de 2-aril-4-hidroxi-1,3-tiazol útiles como inhibidores de TRPM8 en el tratamiento de neuralgia, dolor, EPOC y asma
ES2959690T3 (es) 2015-06-11 2024-02-27 Agios Pharmaceuticals Inc Procedimientos de uso de activadores de piruvato cinasa
AU2016281346B2 (en) * 2015-06-23 2020-01-02 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, or pharmaceutically acceptable salt thereof
EP3184524A1 (en) * 2015-12-21 2017-06-28 Dompé farmaceutici S.p.A. 4-hydroxy-2-phenyl-1,3-thiazol-5-yl methanone derivatives as trpm8 antagonists
ES2855032T3 (es) * 2016-11-02 2021-09-23 Janssen Pharmaceutica Nv Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de PDE2
WO2019043164A1 (de) 2017-08-31 2019-03-07 Basf Se Verwendung physiologischer kühlwirkstoffe und mittel enthaltend solche wirkstoffe
EP3964504A4 (en) * 2019-04-30 2022-12-28 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. AMINOPYRIMIDINE COMPOUND, METHOD OF PRODUCTION THEREOF AND USE THEREOF
AU2021305165A1 (en) * 2020-07-06 2023-02-02 Tactogen Inc Advantageous benzothiophene compositions for mental disorders or enhancement
RU2756587C9 (ru) * 2021-02-12 2021-10-12 Акционерное общество "Отисифарм" Производные 2-ацетамидо-6-гидрокси-бензотиофена и их фармацевтически приемлемые соли, обладающие противовирусной активностью
GB202117129D0 (en) * 2021-11-26 2022-01-12 Epidarex Exeed Ltd Compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725141D0 (en) * 1997-11-27 1998-01-28 Pharmacia & Upjohn Spa Benzenesulfonamide compounds
DE10215321A1 (de) 2002-04-02 2003-10-23 Metagen Pharmaceuticals Gmbh Trp-p8 Splice Varianten und regulatorische RNA
WO2006040103A1 (en) 2004-10-13 2006-04-20 Bayer Healthcare Ag Use of cold menthol receptor modulators for the treatment of respiratory disorders
CA2583015A1 (en) * 2004-10-13 2006-04-20 Bayer Healthcare Ag Substituted 4-benzyloxy-phenylmethylamide derivatives as cold menthol receptor-1 (cmr-1) antagonists for the treatment of urological disorder
EP1911753A1 (en) * 2005-07-29 2008-04-16 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
WO2007017094A1 (en) * 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted benzyloxy-phenylmethylcarbamate derivatives
WO2007017093A1 (en) 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted 2-benzyloxy-benzoic acid amide derivatives
WO2007017092A1 (en) * 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted 4-benzyloxy-benzoic acid amide derivatives
CA2651865C (en) * 2006-05-10 2015-11-24 Janssen Pharmaceutica N.V. Cold menthol receptor-1 antagonists

Also Published As

Publication number Publication date
JO2853B1 (en) 2015-03-15
AU2008275927B2 (en) 2014-08-07
MX2010000690A (es) 2010-06-25
ECSP109921A (es) 2010-02-26
US20090264474A1 (en) 2009-10-22
IL203295A (en) 2015-09-24
US9434711B2 (en) 2016-09-06
NZ582555A (en) 2012-06-29
AU2008275927B8 (en) 2014-08-14
JP2010533734A (ja) 2010-10-28
EP2183239A1 (en) 2010-05-12
KR20100049598A (ko) 2010-05-12
US8809327B2 (en) 2014-08-19
CN101801949A (zh) 2010-08-11
TWI446909B (zh) 2014-08-01
MY153971A (en) 2015-04-30
NI201000013A (es) 2010-07-22
AU2016204436A1 (en) 2016-07-21
PA8790401A1 (es) 2009-03-31
CA2693159A1 (en) 2009-01-22
GT201000015A (es) 2012-03-12
UY31239A1 (es) 2009-03-31
WO2009012430A1 (en) 2009-01-22
US20120190674A1 (en) 2012-07-26
BRPI0815096A2 (pt) 2015-07-14
AU2014203797A1 (en) 2014-07-31
US20140315899A1 (en) 2014-10-23
US8153682B2 (en) 2012-04-10
EP2183239B1 (en) 2012-08-22
JP5539868B2 (ja) 2014-07-02
KR101538391B1 (ko) 2015-07-21
ZA201001157B (en) 2011-04-28
CA2693159C (en) 2016-05-24
CN101801949B (zh) 2014-09-24
AU2008275927A1 (en) 2009-01-22
CO6251375A2 (es) 2011-02-21
CR11284A (es) 2010-08-18
TW200918045A (en) 2009-05-01
AR067602A1 (es) 2009-10-14
CL2008002132A1 (es) 2009-03-06
EA201070158A1 (ru) 2010-08-30

Similar Documents

Publication Publication Date Title
JO2853B1 (en) Sulfonamides as TRPM8 organizations
MA32505B1 (fr) 5-alcynyl-pyrimidines
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
PH12013500745A1 (en) Azaadamantane derivatives and methods of use
MA32811B1 (fr) Nouveaux composés
MY153915A (en) Organic compounds
MX2009012082A (es) Compuestos de ariloazol-2-il cianoetilamino, metodo para prepararlos y metodo para utilizarlos.
TN2012000575A1 (en) Compositions and methods for modulating the wnt signaling pathway
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
PT2139334E (pt) Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos
AU2008303600A8 (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
WO2007138282A3 (en) Bi-aryl or aryl-heteroaryl substituted indoles
MX2010005649A (es) Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
EA200900090A1 (ru) Бензиламины, способ их получения и их применение в качестве противовоспалительных средств
HN2011001606A (es) Antagonistas de 4-azetidinil -1-heteroaril -ciclohexanol de ccr2
WO2009124962A3 (en) Sulfonamides
IN2012DN03846A (uk)
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
DK2190426T3 (da) Griseofulvin-analoger til behandling af cancer ved hæmning af centrosomal clusterdannelse
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists
MX2010004487A (es) Derivados lactamicos sustituidos y sus usos para glaucoma e hipertension ocular.
IN2015DN01230A (en) Pyrrolopyrazoles as n type calcium channel blockers
WO2008131946A3 (de) Substituierte amid-derivate
WO2010021882A3 (en) Cold menthol receptor antagonists
ATE521609T1 (de) Aminothiazolylpyrimidinderivate und ihre verwendung bei der behandlung von krebs